Navigation Links
OncoGenex Pharmaceuticals to Present at RBC Capital Markets' Healthcare Conference
Date:3/1/2010

account);s.linkTrackVars='prop5,eVar3,prop15';s.prop5='External Link';s.eVar3=s.prop5;s.prop15='85801917';s.tl(this,'o','ExternalLink');" target='_blank' href="http://ir.oncogenex.com">http://ir.oncogenex.com. A webcast replay will be available approximately two hours after the call and will be archived for 30 days.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical have entered a global collaboration and license agreement to develop and commercialize OncoGenex's lead drug candidate, OGX-011. The companies expect to initiate two Phase 3 trials in castrate resistant prostate cancer in 2010, and a third Phase 3 trial in non-small cell lung cancer in early 2011; OGX-427 is in Phase 1 clinical development; SN2310 has completed a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

More information about OncoGenex is available at

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
2. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
3. OncoGenex Reports Third Quarter 2009 Financial Results
4. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
5. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
6. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
7. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
8. OncoGenex Reports Second Quarter 2009 Financial Results
9. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
10. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
11. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics ... a life sciences company that develops and commercializes proprietary ... its financial and operational results for the fiscal first ... press release are in Canadian dollars (CAD), unless otherwise ... continued to win new business from our existing customers ...
(Date:2/26/2015)... 26, 2015   Regulus Therapeutics Inc . (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, today ... and Chief Executive Officer of Regulus, will present a ... Annual Healthcare Conference on Wednesday, March 4, 2015 ... at the Boston Marriott Copley Place.  ...
(Date:2/26/2015)... FT. LAUDERDALE, Fla. , Feb. 26, 2015 /PRNewswire/ ... discussed growth priorities driven by key research advancements ... Health segments at today,s Bank of America Merrill Lynch ... worldwide met the challenge of building grain supplies the ... expected to continue at the pace of the last ...
(Date:2/26/2015)... On behalf of biotech client GenScript USA, ... & Spitzer, P.A. (Wilentz) secured a significant jury ... in excess of $10 million. The jury determined that ... that it improperly hired one or more of GenScript’s ... for judgment notwithstanding the verdict, a new trial, and ...
Breaking Biology Technology:SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... Calif., Nov. 20 Cepheid (Nasdaq:,CPHD) will present at ... at 9 a.m. ET at The Pierre Hotel in ... R. Sluis, Senior Vice President,Finance and Chief Financial Officer, ... with accompanying presentation slides, may also be,accessed on Cepheid,s ...
... Revenues Up 61%, Six-Month Net Revenues Up 40%, ETHEX Corporation Net Revenues Up 102% for Second ... ... 14% for Six ... Months, ST. LOUIS, Nov. 20 KV Pharmaceutical Company,(NYSE: KVa/KVb) today reported ...
... FULLERTON, Calif., Nov. 19 Beckman Coulter,Inc. (NYSE: ... marketer of,products that simplify, automate, and innovate complex ... director of investor,relations, will present at the 19th ... 2007, at 8:00 a.m. (ET). (Logo: ...
Cached Biology Technology:Cepheid to Present at the Piper Jaffray 19th Annual Healthcare Conference 2KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 2KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 3KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 4KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 5KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 6KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 7KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 8KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 9KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis 10Beckman Coulter to Present at the 19th Annual Piper Jaffray Healthcare Conference 2
(Date:3/2/2015)... 2, 2015   Neurotechnology , a provider of ... SentiGaze Software Development Kit (SDK). The SentiGaze ... use off-the-shelf webcams to track eye movements and generate ... monitor. Heatmaps can be used for applications such as ... advertising. The SDK can also be used to develop ...
(Date:2/24/2015)... 2015 This report analyzes the worldwide markets for Face ... Biometrics, and Voice Biometrics. The report provides separate comprehensive analytics for ... , Europe , Asia-Pacific , ... , and Latin America . Annual estimates and ... seven-year historic analysis is provided for these markets. Market data and ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
Breaking Biology News(10 mins):Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3
... tomatoes taste like heirlooms, reports an international research team headed ... finding, which will be reported in the June 29 issue ... the U.S. tomato industry, which annually harvests more than 15 ... "This information about the gene responsible for the trait ...
... of a hurricane or major tropical storm passing nearby during ... abnormal health conditions at birth, according to a study led ... the effects of stress on pregnancy. , The study used ... born in the state between 1996 and 2008 whose mothers ...
... (HML) and four partner organizations have measured for the ... five different endangered species of sea turtles. While PFC ... the levels of the compounds seen in all five ... effects in other animals. PFCs are man-made compounds ...
Cached Biology News:Discovery may lead to new tomato varieties with vintage flavor and quality 2Study offers new insights into the effects of stress on pregnancy 2Study offers new insights into the effects of stress on pregnancy 3Study offers new insights into the effects of stress on pregnancy 4Pollutants could pose health risks for 5 sea turtle species 2Pollutants could pose health risks for 5 sea turtle species 3
... consists of an anodized aluminum body in ... Compounds embedded in polymerized matrix. It is ... and Synergy Multi-Detection Readers. This multi-functional test ... reducing the need for tedious wet testing. ...
... SMZ line is a Greenough stereomicroscope designed for ... is available with a choice of a large ... base (N2GG). This microscope can be easily connected ... at the same time giving you ultimate flexibility. ...
... MATra-si Reagent optimized for siRNA applications, contains ... with the nucleic acid of interest. Exploiting ... is then rapidly drawn towards and delivered ... transfection. MATra-si Reagent can be used for ...
...
Biology Products: